Scientists from The Scripps Research Institute (TSRI) have found in animal models that a single gene plays a surprising role in aging that can be detected early on in development, a discovery that could point toward the possibility of one day using therapeutics, even some commonly used ones, to manipulate the aging process itself.
“We believe that a previously uncharacterized developmental gene known as Spns1 may mediate the aging process,” says Shuji Kishi, MD, PhD, who led the study, published recently by the journal PLOS Genetics. “Even a partial loss of Spns1 function can speed aging.”
Using various genetic approaches to disturb Spns1 during the embryonic and/or larval stages of zebrafish, the scientists were able to produce some models with a shortened life span, and others that lived long lives. While most studies of “senescence”—declines in a cell's power of division and growth—have focused on later stages of life, the study is intriguing in exploring this phenomenon in early stages. “Mutations to Spns1 both disturb developmental senescence and badly affect the long-term bio-chronological aging process,” Kishi says.
The new study shows that Spns1, in conjunction with another pair of tumor suppressor genes, beclin 1 and p53, influences developmental senescence through two differential mechanisms: the Spns1 defect was enhanced by beclin 1 but suppressed by “basal” p53. In addition to affecting senescence, Spns1 impedes autophagy, the process whereby cells remove unwanted or destructive proteins and balance energy needs during various life stages. Building on their insights from the study, Kishi and his colleagues note that in the future, therapeutics might be able to influence aging through Spns1. Read the article.
Read more
